Current Price Data+
|Price Movement||- ( No change )|
- +Security prices are delayed by least 20 minutes and are indicative only.
Imugene Limited (IMU) is an Australian immuno-oncology focused Biopharmaceutical Company developing HER2 + ve gastric and breast cancer vaccines. The Group’s lead product is HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu.
|Year to Jun||NPAT||EPS||EPS chg (%)||PER||DPS||Yield (%)||Franking (%)|
|Company||Mkt Cap||EPS Growth (%)||P/E (%)||Dividend Yield (%)|
|2013 A||2014 F||2015 F||2013 A||2014 F||2015 F||2013 A||2014 F||2015 F|
|Monash IVF Group (MVF)||$423M||1.8016||0.1736||0.0347||17.4103||14.8347||14.3371||3.87%||4.72%||4.89%|
|Sirtex Medical (SRX)||$1,698M||0.6876||0.4570||0.4483||42.5395||29.1974||20.1605||0.67%||1.00%||1.45%|
|Earnings||P/E Ratio||P/B Ratio||P/E Growth|
|Mr Charles Walker||Chief Executive Officer, Managing Director||30 Jan 2015|
|Mr Paul Hopper||Executive Chairman||31 Oct 2012|
|Dr Anton Uvarov||Non-Executive Director||5 Jan 2016|
|Dr Axel Hoos||Non-Executive Director||20 Dec 2013|
|Phillip Hains||Chief Financial Officer,Joint Company Secretary|
|Justyn Stedwell||Company Secretary|
|77,000,000 (6.55%)||WebInvest Pty Ltd|
|69,796,875 (5.25%)||Paul Hopper|
Calendar of Events
|27 February 2017||Report (Interim)|
|29 August 2016||Report (Prelim)|
|29 August 2016||Report (Annual)|
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.